TARS Stock Summary and Trading Ideas (Tarsus Pharmaceuticals | NASDAQ:TARS)

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Tarsus Pharmaceuticals trades on the NASDAQ stock market under the symbol TARS.

As of January 7, 2026, TARS stock price declined to $78.08 with 697,729 million shares trading.

TARS has a beta of 0.12, meaning it tends to be less sensitive to market movements. TARS has a correlation of 0.00 to the broad based SPY ETF.

TARS has a market cap of $3.30 billion. This is considered a Mid Cap stock.

Last quarter Tarsus Pharmaceuticals reported $119 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.04.

In the last 3 years, TARS traded as high as $85.25 and as low as $11.33.

The top ETF exchange traded funds that TARS belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

TARS has outperformed the market in the last year with a return of +38.9%, while the SPY ETF gained +17.0%. In the last 3 month period, TARS beat the market returning +15.3%, while SPY returned +3.0%. However, in the most recent 2 weeks TARS has underperformed the stock market by returning -4.9%, while SPY returned +0.2%.

TARS support price is $77.76 and resistance is $82.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TARS shares will trade within this expected range on the day.